Pancreatic Ductal Adenocarcinoma Clinical Trials

75 recruiting

Pancreatic Ductal Adenocarcinoma Trials at a Glance

155 actively recruiting trials for pancreatic ductal adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Phase 2 with 64 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running pancreatic ductal adenocarcinoma studies include City of Hope Medical Center, Minia University, and Revolution Medicines, Inc..

Browse pancreatic ductal adenocarcinoma trials by phase

Treatments under study

About Pancreatic Ductal Adenocarcinoma Clinical Trials

Looking for clinical trials for Pancreatic Ductal Adenocarcinoma? There are currently 75 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Ductal Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Ductal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 155 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 1

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.160 enrolled17 locationsNCT07021066
Recruiting
Phase 1Phase 2

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

MelanomaHead and Neck Squamous Cell CarcinomaPancreatic Ductal Adenocarcinoma
Ipsen220 enrolled12 locationsNCT06305247
Recruiting
Phase 1Phase 2

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute35 enrolled1 locationNCT07214298
Recruiting
Phase 2Phase 3

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121
Recruiting
Phase 1Phase 2

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Esophageal CancerGastric CancerPancreatic Ductal Adenocarcinoma
Perspective Therapeutics112 enrolled7 locationsNCT06710756
Recruiting
Phase 1

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma+1 more
National Cancer Institute (NCI)43 enrolled26 locationsNCT05685602
Recruiting
Phase 2

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE105 enrolled10 locationsNCT07255404
Recruiting
Phase 1

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Pancreatic Ductal Adenocarcinoma
Novartis Pharmaceuticals180 enrolled7 locationsNCT07261631
Recruiting
Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Gastric CancerAdvanced Solid TumorNon-small Cell Lung Cancer+4 more
AstraZeneca70 enrolled15 locationsNCT06147037
Recruiting

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute100 enrolled2 locationsNCT06320717
Recruiting
Phase 1

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic CancerMetastatic Pancreatic Ductal AdenocarcinomaCancer of the Pancreas
Washington University School of Medicine51 enrolled1 locationNCT06648434
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled3 locationsNCT07562152
Recruiting
Not Applicable

Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer

Advanced Pancreatic Ductal AdenocarcinomaCancer Anorexia-Cachexia Syndrome
Shandong Cancer Hospital and Institute56 enrolled1 locationNCT07408505
Recruiting
Phase 2Phase 3

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Metastatic Pancreatic Ductal AdenocarcinomaCachexia
Pfizer982 enrolled114 locationsNCT06989437
Recruiting
Not Applicable

Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening

Pancreatic Ductal AdenocarcinomaPancreas CancerHereditary Diseases+1 more
Lipidica, a.s.419 enrolled16 locationsNCT06549725